T
he 2008 Health Tracking Physician Survey revealed that 53% of all physicians surveyed were willing to accept new Medicaid patients.
1 Another study demonstrated an even lower Medicaid acceptance rate (32%) among US dermatologists.
2 Such low acceptance rates are reflective of considerably lower and delayed reimbursements, increased paperwork and billing requirements, and the high clinical burden of Medicaid patients, 3 all of which have contributed to significant barriers in accessing dermatologic care among this patient population. In 2010, the Patient Protection and Affordable Care Act 4 was signed into law, expanding Medicaid eligibility to include individuals and families with income levels up to 133% of the federal poverty level and expanding the Children's Health Insurance Program to include an additional 4 million children.
We sought to assess the disparities in access to dermatologic care according to patient insurance type and to determine whether a difference in acceptance rates and wait times exists among academic and private dermatologists.
Methods. Study Sample. We obtained a list of dermatologists practicing in Ohio from the American Academy of Dermatology (AAD) directory. A total of 204 dermatologists were included in our study.
After randomizing the dermatologists into 2 groups, we telephoned each, posing as a patient, to request a selfreferred, new-patient appointment for a changing mole. One group of dermatologists was told that patient had CareSource insurance, the largest Medicaid provider in Ohio, and the second group was told that the patient had Anthem Premier Plus PPO, a private insurance plan. We recorded (1) whether the dermatologist was willing to accept the new patient and (2) the number of days before the first available appointment. Finally, we noted whether the dermatologist was part of an academic or private practice. Dermatologists were not informed that the call was being made for the purpose of a study.
Group practices were called once, unless unique numbers for different partners were listed in the AAD directory.
The institutional review board of the Ohio State University approved the protocol.
Results. Participant Characteristics. Of the 204 dermatologists included in our study, 100 were randomized into the private insurance (Anthem) group, while 104 were randomized into the public insurance (CareSource) group. Twenty-nine of these dermatologists practice in an academic setting, while 175 practice in a private setting. Acceptance Rates. Privately insured patients enjoyed a 91.0% overall acceptance rate, while the publicly insured were limited to a 29.8% acceptance rate ( Table 1) .
Appointment Wait Times. The average wait time for a patient with Anthem was significantly less, at 30.54 days (n = 91), than that for a new patient with CareSource (66.42 days; n=31) ( Table 2) .
The average wait time was substantially greater for academic dermatologists (60.5 days) than for private dermatologists (34.01 days) ( Table 3) .
Academic vs Private Dermatologists. Sixteen of the 29 academic dermatologists in our study were randomized to the public insurance group and all 16 were willing to accept a new patient with CareSource, leading to an acceptance rate of 100%. Eighty-eight of the 175 private dermatologists were randomized to the public insurance group, and only 15 were willing to Comment. While privately insured patients enjoyed a 91% acceptance rate and relatively shorter wait times, the publicly insured patients faced significantly lower acceptance rates and longer appointment wait times. Despite making up less than 20% of the workforce, academic dermatologists provide most of the care for Medicaid patients in Ohio. Not only does this limit access to care for the publicly insured, but it also places significant strain on academic dermatology. In addition, the lower reimbursement, and resulting lower physician compensation, may make it more difficult for academic centers to recruit and retain faculty.
The burden faced by academic dermatologists is evident in the data-with an average wait time almost twice that of private dermatologists. With implementation of the health care reform bill and expansion of Medicaid eligibility, longer appointment wait times are inevitable, not only for those with public insurance, but also for those who need the subspecialty care that is often available only at academic centers. 
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Topical Aprepitant in Clinical and Experimental Pruritus
P eroral aprepitant is a nonpeptide inhibitor of tachykinin receptor NK1 approved for use as an antiemetic drug for chemotherapy-induced nausea. Duval and Dubertret 1 first reported that peroral aprepitant effectively reduced pruritus in 3 patients with Sézary syndrome. Similar results were obtained later for 6 of 7 patients with erythrodermic cutaneous T-cell lymphoma.
2 Ständer et al 3 reported an open-label study of 20 patients with chronic pruritus treated for a week with peroral aprepitant. It has been suggested that the effects of aprepitant are related to its preventing of mast-cell activation in the skin. 4 The aim of the present study was to test this hypothesis with topical aprepitant.
Methods. The experimental protocol for both patients and healthy subjects was designed as a randomized, double-blind, vehicle controlled, right-left study and was approved by the local ethics committee. All participants gave their written informed consent. Aprepitant was blended at a 5% concentration in a lipophilic vehicle in accordance with the European Union Good Manufacturing Practice rules. A visual analog scale (VAS) was used to score pruritus.
Thirteen patients (8 women and 5 men; age range, 33-82 years; median age, 57 years) treating 15 symmetrical skin regions completed the study (Table) . The patients received 2 boxes marked "left" and "right," respectively, each containing 3.5 g of a cream to apply topically on a single occasion. They were asked to evaluate their pruritus before, 30 minutes after, and 2 hours after the treatment.
Seven healthy nonatopic volunteers (6 women and 1 man; age range, 37-56 years; median age, 52 years) were enrolled. Aprepitant and the vehicle were applied to the volar surface of the left and right forearms, respectively, and left on for 30 minutes. The cream was then wiped off, and transepidermal water loss (TEWL) was measured using a closed-chamber device (VapoMeter, Delfin Technologies Ltd) to study the effects of the cream on the skin barrier. Thereafter, both forearms were pricked with histamine. The flare and itch were evaluated after 5 minutes, the weal after 15 minutes. 
